Everything SD
Shipping Containers, Straw, and Robots: The Future of San Di...
Read article
Featured articles
Food & Drink
Food News
Food & Drink
Featured articles
Everything SD
Everything SD
Everything SD
Featured articles
Things to Do
Food & Drink
Things to Do
What's next
Featured articles
podcast-ep
video
podcast-ep
Featured articles
Everything SD
Features
Features
Featured articles
Partner content
Everything SD
Partner content
Ready to know more about San Diego?
SubscribeReady to know more about San Diego?
Cidara Therapeutics’ experimental drug cut flu risk by 76 percent in a trial. Now researchers are testing whether it can protect the most vulnerable.
In a trial last flu season, a San Diego biotech company gave healthy adults one dose of an experimental drug before the virus arrived. Over the next 24 weeks, only eight people who received the highest dose developed symptomatic, lab-confirmed flu. In the placebo group, 33 got sick. That amounted to a 76 percent lower risk in the treated group.
The results were strong enough to attract American pharmaceutical company Merck, which bought the Sorrento Valley–based company, Cidara Therapeutics, for about $9.2 billion in January. But the drug’s hardest test is still underway: whether it can protect the people most likely to become seriously ill from the flu.
The flu infects about a billion people a year globally and kills a few hundred thousand—a stat that’s surprising to learn, even as a practicing physician.
Each year, virologists and epidemiologists study the last season and make their best guess at which strains will dominate the next while pharmaceutical companies build the vaccine around this hypothesis. A good guess makes a shot that works; a bad one swings at a ghost—and we’ve been swinging at a solution for a long time.
Modern influenza vaccines arrived in the 1940s, and for decades the annual shot was the entire defensive plan. Then came antivirals, which shorten and decrease the severity and duration of symptoms for people who are already sick, but they’re not a cure. Next, influenza pandemics sent labs scrambling, followed by long, mostly losing hunts for one vaccine to cover every strain.

So Cidara approached the problem from another direction. Its founding idea originated in immunotherapy, the science of turning the body’s own weapons into medicine. Its first success was an antifungal, which kills Candida yeast by weakening its cell walls. The flu came later, and the result is a drug developed as CD388 (investors are careful not to call it a vaccine), which is an antiviral designed to prevent illness. It does not train the immune system the way a vaccine does. Instead, it targets neuraminidase, an enzyme the flu virus uses to release new copies of itself from an infected cell and spread throughout the body. Block that exit, and the virus has a harder time spreading. The copies still get made, but they stay stuck at the door.
The concept itself isn’t new. Other flu drugs, Tamiflu (oseltamivir) and Relenza (zanamivir), have targeted that same enzyme since the late 1990s. What Cidara changed is the delivery. CD388 welds zanamivir onto an engineered piece of human antibody that keeps it in the bloodstream for months. One shot can cover most of a flu season, and because every strain of flu relies on that same enzyme, the drug adapts to them all.
That possibility has led Cidara to describe CD388 as an antiviral designed for “universal prevention” of seasonal and pandemic flu. It’s a tempting shorthand, though experts are not sure it represents the full picture. Laboratory research suggests it can act against a broad range of influenza A and B viruses. What it can do across strains and patients in the real world is a separate question.
“‘Universal’ describes the mechanism, not a proven result,” says Laya Reddy, MD, an infectious disease specialist with Scripps Health. “The preliminary results are promising, but a mechanism that should stop every strain in the lab is not the same as a drug proven to protect every kind of patient across a full season.”
Because CD388 blocks a part of the virus shared by every influenza strain, the approach is, in theory, strain-agnostic. But more research is needed. “So far we do have strong data in healthy adults, but not in the people who need it most,” explains Reddy.
In the summer of 2025, Cidara reported data from a trial of more than 5,000 healthy, unvaccinated adults. The report measured the reduction in symptomatic, lab-confirmed flu compared with placebo over 24 weeks, with a secondary analysis suggesting protection continued through 28 weeks. There were no reported serious side effects tied to the drug, and protection held up for close to seven months. Those are encouraging findings, but the trial was not designed to show whether the drug prevents hospitalization or death, or how well it works in people at greater risk. It was built to prove the concept and pick a dose.
A larger Phase 3 study called ANCHOR is now testing whether the same protection holds in the people who need it most: adults and teenagers at high risk of severe flu. And there is the deeper problem of fighting a virus that has spent a century proving it can change.
The virus is a survivor. “Influenza is a champion at evolving under pressure,” Reddy says. “We’ve seen it develop resistance to antivirals before.” A drug that leans on a single mechanism hands the virus one target to defeat, and nobody yet knows what happens when the same shot is given season after season.
Open questions and all, the numbers were strong enough to attract the attention of Merck. The deal made headlines as a biotech jackpot.
The drug is currently not a replacement for the annual vaccine, but it’s a potential addition to flu prevention.
And of course, owning the drug is not the same as knowing what it will become. Even if the ANCHOR trial succeeds, CD388 is unlikely to put the annual shot into retirement right away. “The realistic picture here is a complement, another tool, especially for the people in whom vaccines serve poorly,” Reddy says. Vaccines still do things this drug does not, and until there is more long-term data, replacing them is not on the table.
That points toward the people with the most to gain. “The people for whom influenza is genuinely dangerous are also the ones for whom vaccines underperform,” Reddy says. CD388 could make flu seasons a lot more stable for the young, elderly, or immunocompromised.
Merck has made a substantial bet on that difference. ANCHOR will show whether the protection that drew its attention holds up in higher-risk patients. If it does, a drug developed in San Diego could give doctors another way to help people through flu season.
Ingrid Yang, M.D., J.D. is a hospital-based physician in San Diego, CA, certified yoga therapist, and longevity specialist. She loves *double hearts* San Diego and spends her days helping people fully engage in long, healthy lives through evidence-based lifestyle medicine. Her books include Adaptive Yoga, Zen Mindfulness, and Hatha Yoga Asanas. When she’s not leading international wellness retreats, she is chasing sunsets, handstanding in nature, or geeking out over mitochondria.
Everything SD
Read article
Food & Drink
Read article
Everything SD
Read article
Things to Do
Read article
Everything SD
Read article
Food News
Read article
Everything SD
Read article
Everything SD
Read article
Food & Drink
Read article
Everything SD
Read article
Food & Drink
Read article
Food & Drink
Read article